RE: RE: Does this have a chance? Glad to see some serious discussion on the BB again. From Feb. NR:
Ascites reduction in the OCC-1 model using the liposomal formulations ranged from 80 to 88 per cent. In comparison the Carboplatin control group was found to reduce ascites by 42 per cent. Peritoneal ascites is a significant cause of morbidity in women with ovarian cancer, and is associated with other cancers and gastrointestinal diseases, representing expanded clinical potential. Tumour burden in the OCC-1 model was reduced by 62 per cent with enhanced Gap107B8 whereas Carboplatin reduced tumour burden by 72 per cent.